Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1Hervé Rubie, Bruno De Bernardi, Mary Gerrard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter StudyRochelle Bagatell, Kieran McHugh, Arlene Naranjo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Rochelle Bagatell, Susan L Cohn, et al.Pediatric Blood & Cancer|July 29, 2024
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter studyAndres F Espinoza, Rochelle Bagatell, Kieran McHugh, et al.Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.Pageof 4